IRIS
PITINI, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.425
EU - Europa 2.781
AS - Asia 2.240
SA - Sud America 938
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 10.456
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.369
SG - Singapore 953
BR - Brasile 839
IE - Irlanda 711
SE - Svezia 691
CN - Cina 675
UA - Ucraina 343
HK - Hong Kong 301
DE - Germania 285
GB - Regno Unito 153
FI - Finlandia 150
IT - Italia 125
RU - Federazione Russa 124
VN - Vietnam 95
FR - Francia 44
BE - Belgio 39
IN - India 36
AR - Argentina 35
BD - Bangladesh 25
MX - Messico 23
TR - Turchia 23
ZA - Sudafrica 22
PL - Polonia 21
CZ - Repubblica Ceca 18
EC - Ecuador 18
IQ - Iraq 18
JP - Giappone 17
AT - Austria 16
CA - Canada 16
NL - Olanda 16
UZ - Uzbekistan 13
MA - Marocco 12
VE - Venezuela 12
AZ - Azerbaigian 11
CO - Colombia 9
ES - Italia 9
TN - Tunisia 9
PK - Pakistan 8
PY - Paraguay 8
IL - Israele 7
KE - Kenya 7
PE - Perù 7
LT - Lituania 6
AE - Emirati Arabi Uniti 5
ID - Indonesia 5
IR - Iran 5
OM - Oman 5
AM - Armenia 4
BO - Bolivia 4
CI - Costa d'Avorio 4
DO - Repubblica Dominicana 4
JO - Giordania 4
NO - Norvegia 4
PA - Panama 4
AL - Albania 3
BN - Brunei Darussalam 3
BY - Bielorussia 3
CL - Cile 3
EG - Egitto 3
LV - Lettonia 3
NP - Nepal 3
PS - Palestinian Territory 3
QA - Qatar 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RO - Romania 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BG - Bulgaria 1
CG - Congo 1
CH - Svizzera 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
ML - Mali 1
MY - Malesia 1
Totale 10.450
Salva come PNG Salva come JPEG
Città #
Dublin 711
Jacksonville 651
Chandler 567
Ashburn 486
Singapore 464
Dallas 448
Nyköping 358
Beijing 302
Hong Kong 299
Ann Arbor 156
Princeton 123
Cambridge 119
Los Angeles 111
Des Moines 100
Dearborn 93
The Dalles 88
Medford 86
Boardman 70
New York 64
Lancaster 61
Woodbridge 60
Munich 59
Messina 55
Buffalo 53
São Paulo 53
Wilmington 39
Brussels 37
Jinan 35
Ho Chi Minh City 33
Moscow 31
Tianjin 30
Redondo Beach 28
Rio de Janeiro 26
Shenyang 26
Houston 24
San Mateo 22
Turku 22
Hanoi 21
Seattle 21
Chicago 20
Belo Horizonte 19
Santa Clara 18
Warsaw 18
Council Bluffs 17
Ningbo 17
Brno 16
Düsseldorf 16
Haikou 16
Nanjing 16
Tokyo 16
Zhengzhou 15
Brasília 14
Nanchang 14
Vienna 14
Auburn Hills 13
Taizhou 13
Atlanta 12
Denver 12
Goiânia 12
Hangzhou 12
Hebei 12
Baku 11
Brooklyn 11
Curitiba 11
Frankfurt am Main 11
Salvador 11
Tashkent 11
Campinas 10
Chennai 10
Guangzhou 10
Johannesburg 10
Porto Alegre 10
Stockholm 10
Baghdad 9
Phoenix 9
Quito 9
Ribeirão Preto 9
San Francisco 9
Boston 8
Buenos Aires 8
Hyderabad 8
Manaus 8
Pune 8
Santo André 8
Bremen 7
Helsinki 7
Joinville 7
Nairobi 7
Norwalk 7
Recife 7
Shanghai 7
São José dos Campos 7
Washington 7
Amsterdam 6
Betim 6
Cape Town 6
Catania 6
Changsha 6
Contagem 6
Da Nang 6
Totale 6.688
Salva come PNG Salva come JPEG
Nome #
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 162
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 157
Emerging markers of cachexia predict survival in cancer patients. 143
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 142
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 139
An accessory spleen wrongly recognised as relapse by positron emission tomography 139
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 135
An acute-leukaemia-like picture due to breast carcinoma cells. 133
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 132
CLINICAL ACTIVITY OF BORTEZOMIB IN RELAPSED OR REFRACTORY GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF MALT TYPE 127
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report 126
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas 124
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 120
Effect of treatment with amifostine in patients with myelodisplastic syndromes on clinical outcome and apoptosis in bone marrow 119
AMIFOSTINE IN CONJUCTION WITH H.D. VP16 AND G-CSF ENABLE PBSC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 118
Trattamento endoscopico scleroterapico nelle neoplasie sanguinanti del tratto digestivo. 118
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 118
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 117
Amifostine in conjuction with G-CSF enhances chemoterapy mobilization of peripheral blood progenitor cell 115
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 114
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 114
A sequential chemoimmunotherapy protocol can obtain a high proportion of molecular remission in chronic lymphocytic leukaemia 112
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 110
ANCHE IN VIVO IL PAMIDRONATO E' UN INDUTTORE DELLA APOPTOSI NELLE PLASMACELLULE MIELOMATOSE 109
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 108
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 107
AN UNUSUAL PRESENTATION OF SCHISTOSOMIASIS 106
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 105
Fatal delayed diagnosis in a patient with falciparum malaria 105
Endobronchial electrocautery for the dehydration of lung cancer. 105
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 104
CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA: CORRELATION WITH DISEASE STAGE 104
Thyroid function, autoimmunity and nodules in hematological malignancies 104
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 103
Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes 102
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 101
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 99
null 99
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 96
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 96
Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients 94
IMATINIB-INDUCED APOPTOSIS IN EOSINOPHILS OF PATIENTS WITH A HYPEREOSINOPHILIC SYNDROME PREDICTS RESPONSE TO TREATMENT 94
Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma 94
Use of bisphosphonates in oncology 94
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 93
Resistance to PGE(2) inhibition of PWM-stimulated lymphocytes from neoplastic patients 92
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 92
Circulating plasma cells in Multiple Myeloma: correlation with disease stage 91
Temozolomide-induced shrinkage of a pituitary carcinoma. 91
null 90
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 90
MORPHOLOGICAL, PHENOTYPIC AND KARYOTYPIC CHARACTERIZATION OF A NOVEL NATURAL-KILLER-CELL TARGET - EVIDENCE OF INVOLVEMENT OF MHC CLASS-I MOLECULES IN NK CELL RECOGNITION 90
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 90
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 88
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 87
OUR EXPERIENCE ON THE EFFECTS OF TAMOXIFEN ON BLOOD COAGULATION IN PATIENTS OPERATED FOR BREAST CANCER Folia Oncologica vol.XIV-n.2-3 (Aprile-Settembre)-1991 87
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 87
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report 87
Acute neurotoxicity as a serious adverse event related to rasburicase in a non-Hodgkin's lymphoma patient 87
How cells respond to interferons. 87
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF 87
Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease 86
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 86
IMMUNOCHEMOTHERAPY WITH RITUXIMAB AND TEMOZOLOMIDE FOR CENTRAL NERVOUS SYSTEM LYMPHOMAS 84
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 83
Myeloid-derived suppressor cells absolute counts in predicting durable response to R-CHOP in patients with follicular lymphoma. 82
null 81
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 81
ANALISI SEQUENZIALE DELLA TRISOMIA 12 NELLA LEUCEMIA LINFATICA CRONICA 80
ADVERSE PROGNOSTIC FACTOR OF p53 GENE DELECTION DETECTED BY FISH IN MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION 80
Spontaneous rupture of spleen during peripheral blood stem cell mobilization in a patient with breast cancer 79
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 79
DIABETIC FOOT DISEASE IN A PATIENT WITH MULTIPLE MYELOMA RECEIVING THALIDOMIDE 78
ALTE DOSI: QUESTIONI APERTE E SVILUPPI FUTURI 78
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 78
null 75
SUCCESSFULL MOBILIZATION OF PERIPHERAL PROGENITOR CELLS WITH PACLITAXEL AND LENOGRASTIM PATIENTS WITH METASTATIC BREAST CANCER 72
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence 72
Immunochemotherapy with temozolomide and rituximab for central nervous system lymphomas in an elderly population. 72
null 72
Single-dose pegfilgrastim after chemotherapy is sufficient for mobilisation of peripheral blood stem cells in patients with multiple myeloma 70
Uso di Bortezomib come terapia di prima linea nella leucemia plasmacellulare primaria 70
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 70
GENE EXPRESSION PROFILING DOES NOT IDENTIFY MOLECULAR SUBGROUP AMONG NODAL PERIPHERAL T-CELL LYMPHOMAS 69
Pitfalls of positron emission tomography for assessing relapse in Hodgkin'sdisease: a case report 69
Sequential treatment with alemtuzumab and rituximab can induce long-term responses in splenic marginal zone lymphoma 69
ERYTHROPOIETIN IN CONJUNCTION WITH H.D. VP16 AND LENOGRASTIM ENABLE PBPC COLLECTION IN MULTIPLE MYELOMA PATIENTS WHO FAILED CTX INDUCED MOBILIZATION 67
MOBILIZZAZIONE DI CELLULE NEOPLASTICHE IN CORSO DI TERAPIA AD ALTE DOSI NEL CARCINOMA DELLLA MAMMELLA. NOSTRA ESPERIENZA. 67
ERYTHROPOIETIN IN COMBINATION WITH LENOGRASTIM AFTER CYCLOPHOSPHAMIDE IMPROVES PERIPHERAL BLOOD PROGENITOR CELL YIELD IN MULTIPLE MYELOMA PATIENT 66
Retrospective analysis of P-STAT6 expression as a predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate. 66
Preliminary results of a phase II study of amifostine for patients with myelodisplastic syndrome 66
Personalized treatment of early-stage non-small-cell lung cancer: The challenging role of EGFR inhibitors 66
Single-dose of pegfilgrastim after chemotherapy is sufficient for mobilization of peripheral blood stem cells in patients with multiple myeloma 65
IMPIEGO DELLA AMIFOSTINE+HD VP16+G-CSF NEI PAZIENTI CON MIELOMA MULTIPLO CHE NON MOBILIZZANO DOPO CTX+G-CSF 65
IMPIEGO DELLA AMIFOSTINA NELLE PROCEDURE DI MOBILIZZAZIONE. NOSTRA ESPERIENZA 64
PIK3CA mutations in breast cancer: A potential predictive marker 64
Risk of second malignant neoplasm among patients with lymphoma 64
RESPONSE TO IMATINIB IN CHRONIC MYELOPROLIFERATIVE DISEASES WITH ACTIVATION OF THE PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR (PDGF betaR) 63
LONG-TERM RESULTS FROM MOPPEBVCAD CHEMOTHERAPY WITH OPTIONAL LIMITED RADIOTHERAPY IN ADVANCED HODGKIN'S DISEASE 63
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. 63
Totale 9.403
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021378 0 0 0 0 0 96 8 84 16 89 57 28
2021/2022848 6 139 18 17 25 3 58 27 5 160 154 236
2022/20232.164 173 209 102 170 187 205 23 136 855 9 71 24
2023/2024445 38 88 29 57 28 83 14 34 3 22 3 46
2024/20252.370 28 34 31 145 106 71 33 597 606 156 183 380
2025/20262.167 325 390 478 362 535 77 0 0 0 0 0 0
Totale 10.585